Market Overview

UPDATE: Dawson James Initiates Celsion at Market Outperform on Phase III Catalyst

Related CLSN
Morning Market Losers
Celsion Announces Potent, Durable Preclinical Lung Expression Data for Its Novel TheraSilence RNA Program
Celsion $8M in direct financing (Seeking Alpha)

Dawson James initiated coverage on Celsion (NASDAQ: CLSN) with a Market Outperform rating and a $9 price target.

Dawson James said, "In our opinion, should the HEAT trial read out positively as we expect, it will not only be viewed by investors as a validation of the market opportunity for ThermoDox, but for the entire clinical development strategy across multiple tumor types with significant commercial potential. It is worth noting that CLSN owns all the worldwide rights to ThermoDox with the exception of Japan. A future corporate collaboration could be yet another material value-driver in a reasonable (12-18 month) investment time horizon."

Celsion closed at $6.66 on Monday.

Latest Ratings for CLSN

Oct 2014Cantor FitzgeraldInitiates Coverage onBuy
Sep 2013HC WainwrightInitiates Coverage onBuy
Jan 2013Roth CapitalDowngradesBuyNeutral

View More Analyst Ratings for CLSN
View the Latest Analyst Ratings

Posted-In: Dawson JamesAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (CLSN)

Around the Web, We're Loving...